Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-101 in healthy volunteers
NCT03835637Phase 1Completed
- Sponsor
- ORIC Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ORIC-101 in solid tumor (7 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Maximum plasma concentration, Area under the curve and 2 more. Started Mar 2018; status: completed.
02
Drugs
ORIC-101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03835637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835637.